Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Rev. Bras. Zootec. (Online) ; 47: e20160382, 2018. tab
Artículo en Inglés | VETINDEX | ID: biblio-1512892

RESUMEN

The objective of this study was to explore the impact of thermal stress on hormonal level and antioxidant activity in goats during various phases of the estrous cycle in the Egyptian summer. Forty cycling does were allocated to two groups (20 animals each) divided by season (mild/hot). Daily meteorological, rectal temperature, and respiratory rate data were recorded in the two seasons. The estrous cycle of the goats was synchronized by two intramuscular injections of 5 mg of prostaglandin F2α (PGF2α) at 11-day intervals. Blood samples were collected every two days and the levels of total antioxidant, malondialdehyde, and ß-carotene were estimated. Total protein, albumin, cholesterol, triglycerides, progesterone, and thyroxine (T4) hormones were additionally measured in the serum of the collected samples. Under hot circumstances, both rectal temperature and respiratory rate increased considerably, with significant variation during the different stages of the estrous cycle. On the other hand, serum level of total protein, albumin, cholesterol, and triglycerides reduced significantly in animals in the hot environment, particularly during the luteal period of the estrous cycle (IV). During the Egyptian hot summer, the serum level of progesterone and T4 hormones declined in phases II and IV of the estrous cycle for progesterone and T4, respectively. Moreover, the serum content of all oxidative stress markers tested (total antioxidant, ß-carotene, and malondialdehyde) decreased considerably, especially in estrous cycle phase II in the hot environment. The Egyptian environmental conditions have detrimental effects on some antioxidant agents and some biochemical parameters throughout the estrous cycle of goats.(AU)


Asunto(s)
Animales , Cabras/fisiología , Estrés Oxidativo/fisiología , beta Caroteno/efectos adversos , Malondialdehído/efectos adversos , Ciclo Estral , Egipto , Antioxidantes
2.
Cochrane Database Syst Rev ; 7: CD011161, 2016 Jul 25.
Artículo en Inglés | MEDLINE | ID: mdl-27455163

RESUMEN

BACKGROUND: 'Keratinocyte cancer' is now the preferred term for the most commonly identified skin cancers basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), which were previously commonly categorised as non-melanoma skin cancers (NMSC). Keratinocyte cancer (KC) represents about 95% of malignant skin tumours. Lifestyle changes have led to increased exposure to the sun, which has, in turn, led to a significant increase of new cases of KC, with a worldwide annual incidence of between 3% and 8%. The successful use of preventive measures could mean a significant reduction in the resources used by health systems, compared with the high cost of the treatment of these conditions. At present, there is no information about the quality of the evidence for the use of these sun protection strategies with an assessment of their benefits and risks. OBJECTIVES: To assess the effects of sun protection strategies (i.e. sunscreen and barrier methods) for preventing keratinocyte cancer (that is, basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) of the skin) in the general population. SEARCH METHODS: We searched the following databases up to May 2016: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trial registries and the bibliographies of included studies for further references to relevant trials. SELECTION CRITERIA: We included randomised controlled clinical trials (RCTs) of preventive strategies for keratinocyte cancer, such as physical barriers and sunscreens, in the general population (children and adults), which may provide information about benefits and adverse events related to the use of solar protection measures. We did not include trials focused on educational strategies to prevent KC or preventive strategies in high-risk groups. Our prespecified primary outcomes were BCC or cSCC confirmed clinically or by histopathology at any follow-up and adverse events. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies for eligibility using Early Review Organizing Software (EROS). Similarly, two review authors independently used predesigned data collection forms to extract information from the original study reports about the participants, methods of randomisation, blinding, comparisons of interest, number of participants originally randomised by arm, follow-up losses, and outcomes, and they assessed the risk of bias. We resolved any disagreement by consulting a third author and contacted trial investigators of identified trials to obtain additional information. We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included one RCT (factorial design) that randomised 1621 participants.This study compared the daily application of sunscreen compared with discretionary use of sunscreen, with or without beta-carotene administration, in the general population. The study was undertaken in Australia; 55.2% of participants had fair skin, and they were monitored for 4.5 years for new cases of BCC or cSCC assessed by histopathology. We found this study to be at low risk of bias for domains such as allocation, blinding, and incomplete outcome data. However, we found multiple unclear risks related to other biases, including an unclear assessment of possible interactions between the effects of the different interventions evaluated (that is, sunscreen and beta-carotene). We found no difference in terms of the number of participants developing BCC (n = 1621; risk ratio (RR) 1.03, 95% confidence interval (CI) 0.74 to 1.43) or cSCC (n = 1621; RR 0.88, 95% CI 0.50 to 1.54) when comparing daily application of sunscreen with discretionary use, even when analyses were restricted to groups without beta-carotene supplementation. This evidence was of low quality, which means that there is some certainty that future studies may alter our confidence in this evidence.We reported adverse events in a narrative way and included skin irritation or contact allergy.We identified no studies that evaluated other sun protection measures, such as the use of sun-protective clothing, sunglasses, or hats, or seeking the shade when outdoors. AUTHORS' CONCLUSIONS: In this review, we assessed the effect of solar protection in preventing the occurrence of new cases of keratinocyte cancer. We only found one study that was suitable for inclusion. This was a study of sunscreens, so we were unable to assess any other forms of sun protection. The study addressed our prespecified primary outcomes, but not most of our secondary outcomes. We were unable to demonstrate from the available evidence whether sunscreen was effective for the prevention of basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC).Our certainty in the evidence was low because there was a lack of histopathological confirmation of BCC or cSCC in a significant percentage of cases. Amongst other sources of bias, it was not clear whether the study authors had assessed any interaction effects between the sunscreen and beta-carotene interventions. We think that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.


Asunto(s)
Carcinoma Basocelular/prevención & control , Carcinoma de Células Escamosas/prevención & control , Neoplasias Inducidas por Radiación/prevención & control , Neoplasias Cutáneas/prevención & control , Luz Solar/efectos adversos , Protectores Solares/administración & dosificación , Adulto , Australia , Niño , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Protectores Solares/efectos adversos , Rayos Ultravioleta/efectos adversos , Vitaminas/administración & dosificación , Vitaminas/efectos adversos , beta Caroteno/administración & dosificación , beta Caroteno/efectos adversos
3.
Eur J Pharm Sci ; 89: 146-53, 2016 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-27130544

RESUMEN

Currently most of sunscreens provide effective protection in the full UV range but lack VIS protection. The addition of effective antioxidants to sunscreens might afford suitable UV-VIS protection. Apigenin (API), chrysin (CRI) and beta-carotene (BTC) have shown potential for UV-VIS protection. This paper reports a photosafety and efficacy screening of such antioxidants through evaluation of the photostability, photoreactivity and phototoxicity as well as UVA/UVB ratio and critical wavelength. The assessment of the photostability, photoreactivity and phototoxicity of API, CRI and BTC, isolated and combined (CMB) was performed by HPLC, ROS assay and 3T3 NRU phototoxicity test, respectively. The phototoxicity test was also performed for CMB plus bemotrizinol (BMZ). The in vitro evaluation of the UVA protection was assessed by the determination of the UVA/UVB ratio and the critical wavelength. The antioxidants API, CRI, BTC and CMB were stable under UVA/VIS and VIS light. However weak photoreactivity after UVA/VIS irradiation was observed for API, CRI and CMB in the ROS assay. In the 3T3 NRU phototoxicity test, phototoxic potential was observed for CRI, BTC, CMB and CMB+BMZ after UVA/VIS exposure, and for BTC and CMB after VIS exposure. BMZ reduced the phototoxic potential of CMB in the VIS range. In the in vitro evaluation of UVA protection API, CRI, BTC, CMB and CMB+BMZ presented ultra UVA protection (UVA/UVB ratio>0.9) and exhibited critical wavelength close to or above 370nm. In conclusion, the use of API, CRI, BTC and their CMB aiming skin photoprotection could be considered safer in the VIS range. Furthermore, API presented the best performance in the photosafety screening among the studied antioxidants, since it was photostable and non-phototoxic in UVA/VIS and photostable, non-photoreactive and non-phototoxic in VIS range.


Asunto(s)
Apigenina/farmacología , Flavonoides/farmacología , Protectores Solares/farmacología , beta Caroteno/farmacología , Animales , Antioxidantes/efectos adversos , Antioxidantes/farmacología , Apigenina/efectos adversos , Línea Celular , Dermatitis Fototóxica/etiología , Estabilidad de Medicamentos , Fibroblastos/efectos de los fármacos , Flavonoides/efectos adversos , Luz/efectos adversos , Ratones , Ratones Endogámicos BALB C , Rojo Neutro/efectos adversos , Rojo Neutro/farmacología , Piel/efectos de la radiación , Protectores Solares/efectos adversos , Rayos Ultravioleta/efectos adversos , beta Caroteno/efectos adversos
4.
Nutrients ; 6(12): 5572-82, 2014 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-25470379

RESUMEN

Despite the antioxidant potential of vitamin A, recent studies reported that chronic retinol ester supplementation can also exert pro-oxidant effects and neurotoxicity in vivo and raises the mortality rates among healthy subjects. Our aim was to find evidence for a safer (i.e., less toxic) molecule with provitamin A activity. Therefore, we investigated whether chronic supplementation of healthy Wistar rats with ß-carotene (0.6, 3, and 6 mg/kg/day) would demonstrate antioxidant characteristics without leading to pro-oxidant side effects in the brain. Total reactive antioxidant potential (TRAP), thiobarbituric reactive species level (TBARS), and total reduced thiol content (SH) were evaluated in plasma. TBARS and SH were additionally evaluated in selected brain regions together with superoxide dismutase (SOD) and catalase (CAT) activity. In the present study, we show that ß-carotene is able to exert antioxidant activity in plasma without triggering pro-oxidant events in the brain, providing evidence that may justify its further evaluation as a safer nutritional supplement with provitamin A activity.


Asunto(s)
Antioxidantes/administración & dosificación , Encéfalo/efectos de los fármacos , Suplementos Dietéticos , Vitamina A/administración & dosificación , beta Caroteno/administración & dosificación , Animales , Antioxidantes/efectos adversos , Biomarcadores/sangre , Encéfalo/metabolismo , Catalasa/metabolismo , Suplementos Dietéticos/efectos adversos , Masculino , Oxidación-Reducción , Estrés Oxidativo/efectos de los fármacos , Ratas Wistar , Medición de Riesgo , Factores de Riesgo , Compuestos de Sulfhidrilo/sangre , Superóxido Dismutasa/metabolismo , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo , Factores de Tiempo , Vitamina A/efectos adversos , beta Caroteno/efectos adversos
5.
Arq. bras. cardiol ; Arq. bras. cardiol;101(3): 233-239, set. 2013. ilus, tab
Artículo en Portugués | LILACS | ID: lil-686545

RESUMEN

FUNDAMENTO: Estudos de intervenção mostraram aumento da mortalidade em pacientes que receberam betacaroteno. Contudo, não são conhecidos os mecanismos envolvidos nesse fenômeno. OBJETIVO: Avaliar a influência do betacaroteno sobre o estresse oxidativo e a expressão de conexina 43 em coração de ratos. MÉTODOS: Ratos Wistar, pesando aproximadamente 100 g, foram alocados em dois grupos: Grupo Controle (n = 30), que recebeu a dieta usada de rotina em nosso laboratório, e Grupo Betacaroteno (n = 28), que recebeu betacaroteno (na forma de cristal, adicionado e misturado à dieta) na dose de 500 mg de betacaroteno/kg de dieta. Os animais receberam tratamento até que atingissem entre 200 e 250 g, quando eram sacrificados. Foram coletados sangue, fígado e coração para realização de Western blotting e imunoistoquímica para conexina 43; foram realizados estudos morfométricos, dosagens de betacaroteno por cromatografia líquida de alta eficiência bem como de glutationa reduzida, glutationa oxidada e hidroperóxidos de lipídeos por análises bioquímicas. RESULTADOS: O betacaroteno foi detectado apenas no fígado dos animais do Grupo Betacaroteno (288 ± 94,7 µg/kg). Os níveis de glutationa reduzida/glutationa oxidada foram maiores no fígado e no coração dos animais do Grupo Betacaroteno (fígado - Grupo Controle: 42,60 ± 1,62; fígado - Grupo Betacaroteno: 57,40 ± 5,90; p = 0,04; coração: - Grupo Controle: 117,40 ± 1,01; coração - Grupo Betacaroteno: 121,81 ± 1,32 nmol/mg proteína; p = 0,03). O conteúdo de conexina 43 total foi maior no Grupo Betacaroteno. CONCLUSÃO: O betacaroteno apresentou efeito benéfico, caracterizado pelo aumento da comunicação intercelular e melhora do sistema de defesa antioxidante. Nesse modelo, os mecanismos não explicam a maior mortalidade observada com a suplementação de betacaroteno em estudos clínicos. (Arq Bras Cardiol. 2013; [online].ahead print, PP.0-0).


BACKGROUND: Intervention studies have shown an increased mortality in patients who received beta-carotene. However, the mechanisms involved in this phenomenon are still unknown. OBJECTIVE: Evaluate the influence of beta-carotene on oxidative stress and the expression of connexin 43 in rat hearts. METHODS: Wistar rats, weighing approximately 100 g, were allocated in two groups: Control Group (n=30), that received the diet routinely used in our laboratory, and Beta-Carotene Group (n = 28), which received beta-carotene (in crystal form, added and mixed to the diet) at a dose of 500 mg of beta-carotene/kg of diet. The animals received the treatment until they reached 200-250g, when they were sacrificed. Samples of blood, liver and heart were collected to perform Western blotting and immunohistochemistry for connexin 43; morphometric studies, dosages of beta-carotene by high-performance liquid chromatography as well as reduced glutathione, oxidized glutathione and lipids hydroperoxides were performed by biochemical analysis. RESULTS: Beta-carotene was detected only in the liver of Beta-Carotene Group animals (288 ± 94.7 µg/kg). Levels of reduced/oxidized glutathione were higher in the liver and heart of Beta-Carotene Group animals (liver - Control Group: 42.60 ± 1.62; liver - Beta-Carotene Group: 57.40 ± 5.90; p = 0.04; heart: - Control Group: 117.40 ± 1.01; heart - Beta-Carotene Group: 121.81 ± 1.32 nmol/mg protein; p = 0.03). The content of total connexin 43 was larger in Beta-Carotene Group. CONCLUSION: Beta-carotene demonstrated a positive effect, characterized by the increase of intercellular communication and improvement of anti-oxidizing defense system. In this model, mechanism does not explain the increased mortality rate observed with the beta-carotene supplementation in clinical studies. (Arq Bras Cardiol. 2013; [online].ahead print, PP.0-0).


Asunto(s)
Animales , Masculino , Ratas , /efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Vitaminas/farmacología , beta Caroteno/farmacología , Western Blotting , /metabolismo , Disulfuro de Glutatión/análisis , Ventrículos Cardíacos/química , Inmunohistoquímica , Peróxidos Lipídicos/análisis , Hígado/química , Ratas Wistar , Remodelación Ventricular , Vitaminas/efectos adversos , Vitaminas/análisis , beta Caroteno/efectos adversos , beta Caroteno/análisis
6.
Arq Bras Cardiol ; 101(3): 233-9, 2013 Sep.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-23917457

RESUMEN

BACKGROUND: Intervention studies have shown an increased mortality in patients who received beta-carotene. However, the mechanisms involved in this phenomenon are still unknown. OBJECTIVE: Evaluate the influence of beta-carotene on oxidative stress and the expression of connexin 43 in rat hearts. METHODS: Wistar rats, weighing approximately 100 g, were allocated in two groups: CONTROL GROUP (n=30), that received the diet routinely used in our laboratory, and Beta-Carotene Group (n = 28), which received beta-carotene (in crystal form, added and mixed to the diet) at a dose of 500 mg of beta-carotene/kg of diet. The animals received the treatment until they reached 200-250 g, when they were sacrificed. Samples of blood, liver and heart were collected to perform Western blotting and immunohistochemistry for connexin 43; morphometric studies, dosages of beta-carotene by high-performance liquid chromatography as well as reduced glutathione, oxidized glutathione and lipids hydroperoxides were performed by biochemical analysis. RESULTS: Beta-carotene was detected only in the liver of Beta-Carotene Group animals (288 ± 94.7 µg/kg). Levels of reduced/oxidized glutathione were higher in the liver and heart of Beta-Carotene Group animals (liver - CONTROL GROUP: 42.60 ± 1.62; liver - Beta-Carotene Group: 57.40 ± 5.90; p = 0.04; heart: - CONTROL GROUP: 117.40 ± 1.01; heart - Beta-Carotene Group: 121.81 ± 1.32 nmol/mg protein; p = 0.03). The content of total connexin 43 was larger in Beta-Carotene Group. CONCLUSION: Beta-carotene demonstrated a positive effect, characterized by the increase of intercellular communication and improvement of anti-oxidizing defense system. In this model, mechanism does not explain the increased mortality rate observed with the beta-carotene supplementation in clinical studies.


Asunto(s)
Conexina 43/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Vitaminas/farmacología , beta Caroteno/farmacología , Animales , Western Blotting , Conexina 43/metabolismo , Disulfuro de Glutatión/análisis , Ventrículos Cardíacos/química , Inmunohistoquímica , Peróxidos Lipídicos/análisis , Hígado/química , Masculino , Ratas , Ratas Wistar , Remodelación Ventricular , Vitaminas/efectos adversos , Vitaminas/análisis , beta Caroteno/efectos adversos , beta Caroteno/análisis
7.
Genet Mol Res ; 12(4): 6402-13, 2013 Dec 10.
Artículo en Inglés | MEDLINE | ID: mdl-24390989

RESUMEN

The radioisotope iodine-131 [(131)I] can damage DNA. One way to prevent this is to increase the amount of antioxidants via dietary consumption. The goal of this study was to evaluate the radioprotective effect of fresh acerola pulp and synthetic beta-carotene in Rattus norvegicus hepatoma cells (HTC) in response to [(131)I] exposure in vitro. Cellular DNA damage was subsequently assessed using a cytokinesis block micronucleus assay. The mutagenic and cytotoxic activities of doses of [(131)I] (0.1, 0.5, 1, 5, and 10 µCi), acerola (0.025, 0.125, and 0.25 g acerola pulp/mL), and beta-carotene (0.2, 1, and 2 µM) were evaluated. Radioprotective tests were performed by simultaneous treatment with acerola (0.25 g/mL) plus [(131)I] (10 µCi) and beta-carotene (0.2 µM) plus [(131)I] (10 µCi). Acerola, beta-carotene, and low concentrations of [(131)I] did not induce micronucleus formation in HTC cells; in contrast, high concentrations of [(131)I] (10 µCi) were mutagenic and induced DNA damage. Moreover, neither acerola nor beta-carotene treatment was cytotoxic. However, acerola reduced the percentage of [(131)I]-induced damage, although beta-carotene did not show a similar effect. Thus, our results suggest that acerola diet supplementation may benefit patients who are exposed to [(131)I] during thyroid diagnostics and therapy.


Asunto(s)
Daño del ADN/efectos de la radiación , Radioisótopos de Yodo/toxicidad , Malpighiaceae/metabolismo , Protectores contra Radiación/farmacología , beta Caroteno/farmacología , Animales , Antocianinas/análisis , Antioxidantes/farmacología , Ácido Ascórbico/análisis , Carcinoma Hepatocelular , Carotenoides/análisis , ADN/efectos de la radiación , Suplementos Dietéticos , Flavonoides/análisis , Radioisótopos de Yodo/farmacología , Neoplasias Hepáticas , Mutación/efectos de la radiación , Preparaciones de Plantas/efectos adversos , Preparaciones de Plantas/farmacología , Ratas , Ratas Wistar , Células Tumorales Cultivadas , beta Caroteno/efectos adversos
8.
Nutrition ; 22(2): 146-51, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16183256

RESUMEN

OBJECTIVE: We studied the effects of beta-carotene (BC) on ventricular remodeling after myocardial infarction. METHODS: Myocardial infarction was induced in Wistar rats that were then treated with a BC diet (500 mg/kg of diet per day; MI-BC; n = 27) or a regular diet (MI; n = 27). Hearts were analyzed in vivo and in vitro after 6 mo. RESULTS: BC caused decreased left ventricular wall thickness (MI = 1.49 +/- 0.3 mm, MI-BC = 1.23 +/- 0.2 mm, P = 0.027) and increased diastolic (MI = 0.83 +/- 0.15 cm2, MI-BC = 0.98 +/- 0.14 cm2, P = 0.020) and systolic (MI = 0.56 +/- 0.12 cm2, MI-BC = 0.75 +/- 0.13 cm2, P = 0.002) left ventricular chamber areas. With respect to systolic function, the BC group presented less change in fractional area than did controls (MI = 32.35 +/- 6.67, MI-BC = 23.77 +/- 6.06, P = 0.004). There was no difference in transmitral diastolic flow velocities between groups. In vitro results showed decreased maximal isovolumetric systolic pressure (MI = 125.5 +/- 24.1 mmHg, MI-BC = 95.2 +/- 28.4 mmHg, P = 0.019) and increased interstitial myocardial collagen concentration (MI = 3.3 +/- 1.2%, MI-BC = 5.8 +/- 1.7%, P = 0.004) in BC-treated animals. Infarct sizes were similar between groups (MI = 45.0 +/- 6.6%, MI-BC = 48.0 +/- 5.8%, P = 0.246). CONCLUSION: Taken together, these data suggest that BC has adverse effects on ventricular remodeling after myocardial infarction.


Asunto(s)
Antioxidantes/efectos adversos , Infarto del Miocardio/patología , Remodelación Ventricular/efectos de los fármacos , beta Caroteno/efectos adversos , Animales , Antioxidantes/farmacología , Suplementos Dietéticos , Corazón/anatomía & histología , Masculino , Miocardio/patología , Distribución Aleatoria , Ratas , Ratas Wistar , Resultado del Tratamiento , Función Ventricular/efectos de los fármacos , Función Ventricular/fisiología , beta Caroteno/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA